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K e y  M e s s a g e s 
1. The use of minocycline to regulate the 
neuropathological effects of systemically 
administered cytokines was studied.
2. Systemic cytokines cause glial activation, and 
reduce tau and drebrin in the hippocampus. 
Minocycline reverses these effects of cytokines, 
suggesting that it may be neuroprotective against 
cytokine storm.
Oral feeding of minocycline attenuates glial 
activation and reductions of tau and drebrin in 
response to systemically injected cytokines
DCH Poon, YS Ho, CF Lau, K Chiu, RCC Chang *
Introduction
Influenza leads to complications not only in the 
respiratory tract, but also within the central nervous 
system (CNS). These influenza-related neurological 
complications (INCs) include encephalopathy, 
encephalitis, and seizures, and affect up to 20% of 
hospitalised children diagnosed with influenza in 
Hong Kong. Febrile seizure is the most common 
type of INC.
 One process that regulates INCs is the 
induction of cytokine storm during influenza.1 A 
cytokine storm is an over-reactive immune response 
characterised by drastic elevations of many systemic 
inflammatory mediators. It has been suggested as the 
cause of multiple organ failure and high mortality 
during the 1918 and 2009 influenza pandemics. 
Infection with influenza viruses has been reported 
to hyper-induce an array of cytokines, ie IL-1β, IL-6, 
and TNF-α, IFN-α, and IFN-γ, and chemokines, 
ie IL-8, MIG, IP-10, MCP-1, and MIP-1α,2 all of 
which can potentially influence the brain to affect 
mood, behaviour, and cognition.3 Both humoral 
and/or neural routes are believed to participate in 
relaying systemic cytokine responses to the brain.3 
We hypothesise that in the course of influenza 
infection, the generation of cytokine storm can lead 
to CNS neural and glial changes that may collectively 
mediate INCs.
 Minocycline is a Food and Drug 
Administration–approved, second-generation, 
semi-synthetic tetracycline analogue that exerts 
antimicrobial, anti-inflammatory, and anti-apoptotic 
properties. It is well tolerated by humans in the 
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treatment of acne vulgaris, rheumatoid arthritis, and 
certain sexually transmitted diseases. Moreover, it is 
a strong inhibitor of microglial activity and readily 
penetrates the blood-brain-barrier. Its efficacy in 
treating various neurodegenerative disorders has 
been tested in animal models and clinical trials. Its 
neuroprotective properties have been reported in 
patients with cerebral ischaemia, spinal cord injury, 
multiple sclerosis, amyotrophic lateral sclerosis, 
Parkinson’s disease, Huntington’s disease, and 
Alzheimer’s disease. Nonetheless, conflicting results 
have also been reported. We aimed to investigate 
whether minocycline protects against INCs by 
focusing on (1) the impacts of cytokine storm, which 
develops during influenza infection, on the brain, 
and (2) whether minocycline can attenuate or even 
reverse these changes.
Methods
This study was conducted from October 2009 to 
March 2012. We injected a mixture of cytokines 
(IL-1β, TNF-α, IL-6, IL-8, IFN-α, MCP-1, MIP-1α) 
intraperitoneally into young male Sprague-
Dawley rats to serve as a model of cytokine storm. 
Minocycline (25 mg/rat) was fed immediately 
before the injection, and the rats were sacrificed and 
their brains collected 1 day later to assess whether 
minocycline could modulate the changes in the 
hippocampus induced by mixed cytokines. 
Reagents and test substances
All recombinant cytokines, ie rat IL-1β/IL-1F2, 
rat TNF-α/TNFSF1A, rat IL-6, rat IFN-α, human 
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CXCL8/IL-8, rat CCL2/JE/MCP-1, and human 
CCL3/MIP-1α were purchased from R&D 
Systems (Minneapolis [MN], USA). Minocycline 
hydrochloride, mouse monoclonal anti-GFAP and 
monoclonal anti-GAPDH antibodies, and rabbit 
polyclonal anti-drebrin antibody were from Sigma-
Aldrich (St Louis [MO], USA). Rabbit polyclonal 
antibodies for p-Tau [pS396] and p-Tau [pT231], 
and Alexa Fluor-488 goat anti-rabbit IgG and 
Alexa Fluor-568 anti-mouse IgG antibodies were 
obtained from Invitrogen (Carlsbad [CA], USA). 
Rabbit polyclonal anti-Iba-1 antibody and mouse 
monoclonal anti-Tau-5 antibody were purchased 
from Wako Pure Chemical Industries (Osaka, 
Japan) and BD PharMingen (California, USA), 
respectively. Horseradish peroxidase–conjugated 
goat anti-rabbit and goat anti-mouse antibodies, and 
anti-fade fluorescent mounting medium were from 
DAKO (Glostrup, Denmark). The protein content 
assay kit and polyvinylidene fluoride membrane 
were obtained from Bio-Rad (Hercules [CA], USA). 
Enhanced chemiluminescence (ECL) detection kit 
was from Amersham (Buckinghamshire, UK).
Animal procedures
All animal procedures were approved by the 
Committee on the Use of Live Animals in Teaching 
and Research of the University of Hong Kong. 
Briefly, male Sprague-Dawley rats (~250 g) were 
purchased from the Laboratory Animal Unit of the 
LKS Faculty of Medicine in the University of Hong 
Kong and housed with three rats per cage. They 
were maintained in a temperature-controlled room 
with a 12-hour light/dark cycle, and were allowed 
to acclimatise for 3 days before the start of the 
experiment. On the day of the experiment, the rats 
were randomly divided into four groups: control 
(n=6), mixed cytokines alone (n=5), minocycline 
alone (n=5), and mixed cytokines plus minocycline 
(n=5). All feeding and injection procedures were 
performed at 11:00 am. Minocycline hydrochloride 
was dissolved in distilled water to a concentration 
of 50 mg/mL. Rats were then orally fed with either 
500 µL water or 500 µL of the minocycline solution 
(ie 25 mg/rat of minocycline), immediately followed 
by an intraperitoneal injection of 500 µL phosphate 
buffered saline (PBS) or mixed cytokines (500 ng/
kg IL-1β, 100 ng/kg TNF-α, 500 ng/kg IL-6, 500 ng/
kg IL-8, 500 IU/kg IFN-α, 20 ng/kg MCP-1, and 10 
ng/kg MIP-1α, in PBS). Rats were returned to their 
home cage, and 24 hours later were sacrificed by 
an overdose of sodium pentobarbital. They were 
perfused with saline for 3 minutes, and brains were 
quickly removed and microdissected on ice. The 
right brain tissue was snap frozen in liquid nitrogen 
and stored at -80ºC for western blot analysis. The left 
brain tissue was fixed in 4% paraformaldehyde at 4ºC 
for 3 days before tissue processing.
Tissue processing, immunofluorescence 
staining, and imaging
After fixation, brain tissue was dehydrated in a 
graded series of ethanol, cleared in xylene, and 
embedded in paraffin. It was cut into 6-micron 
coronal brain sections, dewaxed, and rehydrated. 
Antigen retrieval was performed by heating in 0.01 
M citrate buffer (pH 6.0) with 0.1% Tween-20 at 95ºC 
for 15 minutes. Subsequently, sections were washed 
in PBS. Non-specific binding between antibodies 
and tissues was blocked by 10% normal goat serum 
in PBS for 1.5 hours. Sections were incubated with 
primary antibodies for Tau-5 (1:400), drebrin (1:400), 
Iba-1 (1:500), and glial fibrillary acidic protein 
(GFAP) (1:500) at 4ºC overnight, washed with PBS, 
then Alexa Fluor-488 or -568 added for 1.5 hours. 
Subsequently, sections were washed with PBS, 
stained with 4',6-diamidino-2-phenylindole (DAPI) 
for 15 minutes, washed again, and mounted with 
anti-fade fluorescent mounting medium. Finally, 
sections were examined using confocal microscopy 
(Figs 1 & 2) and under a Zeiss Axioplan 2 microscope 
with a 20X or 40X objective (Figs 3 & 4). 
Western blot analysis
Brain tissue was homogenised in ice-cold lysis buffer 
containing 10 mM Tris-HCl (pH 7.4), 1 mM NaCl, 
20 mM Na4P2O7, 2 mM Na3VO4, 1% Triton-X-100, 
10% glycerol, 0.5% deoxycholate, 0.1% SDS, 1 mM 
phenylmethylsulfonyl fluoride, protease inhibitor 
cocktail and phosphatase inhibitor cocktail, 
centrifuged at 14 000 g at 4ºC for 30 minutes, and the 
supernatant collected. The protein in the cell lysates 
was quantified using the protein content assay kit. 
Afterwards, samples from the same group (n=5/6) 
were mixed, subjected to SDS 10% polyacrylamide 
gel electrophoresis at 140V, and transferred to 
polyvinylidene fluoride membranes. Non-specific 
binding on the membranes was blocked by 5% 
non-fat milk in TBST (TBS-containing 0.1% Tween-
20) for 1 hour. Primary antibodies were diluted in 
TBST and incubated with the membrane as follows: 
p-Tau [pT231] (1:3000), p-Tau [pS396] (1:4000), 
Tau-5 (1:2000), drebrin (1:4000), glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) (1:20 000). 
After washing, the membranes were incubated 
with horseradish peroxidase-conjugated secondary 
antibodies for 1 hour and subsequently developed 
using the ECL western blotting detection kit. 
Densitometry measurements were made using Image 
J software (National Institutes of Health, USA). The 
band intensities were normalised against GAPDH 
and results were expressed as fold of control.
Statistical analysis
Normalised band intensities were analysed by 
one-way ANOVA, followed by Student-Newman-
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Keuls test using SigmaStat (Jandel Scientific [CA], 
USA). Results were considered to be significantly 
different if P<0.05.
Results
Mixed cytokines led to activation of microglia and 
astrocytes at the dentate gyrus, and treatment with 
minocycline appeared to reduce these phenomena. 
Moreover, mixed cytokines reduced both protein 
expression level and immunoreactivity of the 
cytoskeleton-associated proteins tau and drebrin, 
and decreased the phosphorylation of tau at serine-
396 but precipitated no change at threonine-231. 
Minocycline significantly reversed, if not totally, 
the decrements in total tau, p-Tau (pS396), and 
drebrin by mixed cytokines. These results suggest 
that oral administration of minocycline can likely 
reverse the impact of cytokine storm on glia and the 
neuronal cytoskeleton in the brain. Future studies 
are encouraged to verify whether minocycline will 
be useful in alleviating INCs.
Minocycline suppressed mixed cytokine-
mediated glial activation
Systemic injection of mixed cytokines led to 
signs of astrocyte activation (ie increased GFAP 
immunoreactivity and astrocyte number versus 
the control) and microglial activation (ie cell body 
hypertrophy, and thickening of processes versus the 
control) within the dentate gyrus (Fig 1). Minocycline 
alone did not induce any observable differences 
in cell morphology or cell numbers of astrocytes 
and microglia (Figs 1 and 2). When rats were co-
treated with mixed cytokines and minocycline, there 
was decreased astrocyte and microglia activation 
compared with the mixed cytokine group (Figs 1 and 
2).
Minocycline reversed the reduction in Tau-5 
and p-Tau [pS396] immunoreactivities 
caused by mixed cytokines 
We performed western blot analysis (Fig 3) and 
immunofluorescence staining (Fig 4) for Tau-5, 
which serves as an index for total Tau. Mixed 
cytokines reduced Tau-5 protein immunoreactivity 
to 0.74±0.02-fold (P<0.05 versus control group). 
Although minocycline alone did not cause any 
change in Tau-5 protein immunoreactivity, eg 
1.17±0.07-fold, it did attenuate the reduction in 
Tau-5 mediated by mixed cytokines to 1.03±0.1-
fold (P<0.05 versus mixed cytokines group). Such 
changes in protein expression were accompanied 
by a similar change in Tau-5 immunoreactivity in 
the CA3 region. Mixed cytokines reduced Tau-5 
immunoreactivity compared with that of the 
control. Minocycline alone did not appear to affect 
Tau-5 immunoreactivity, but did reduce the drop in 
immunoreactivity when it was co-treated with mixed 
cytokines. Moreover, it should be noted that in both 
the minocycline alone group and the co-treatment 
group, there was increased Tau-5 immunoreactivity 
FIG 1.  Fluorescent images of GFAP positive astrocytes 1 day post-treatment, 
in the dentate gyrus of rats treated with (a) control, (b) mixed cytokines, (c) 25 
mg minocycline, and (d) 25 mg minocycline plus mixed cytokines. Minocycline 
attenuates the increase in GFAP immunoreactivity by mixed cytokines.
(a)
(c)
(b)
(d)
FIG 2.  Fluorescent images of Iba-1 positive microglia 1 day post-treatment, in 
the dentate gyrus of rats treated with (a) control, (b) mixed cytokines, (c) 25 mg 
minocycline, and (d) 25 mg minocycline plus mixed cytokines. Arrows in (b) indicate 
activated microglia, ie hypertrophy of cell body, thickening of processes, in the 
mixed cytokine-treated rats. Minocycline reduces activation of microglia by mixed 
cytokines.
(a)
(c)
(b)
(d)
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in the cell bodies of parenchymal cells. 
 We further verified if there was any change 
in the phosphorylation of Tau at serine-396 and 
threonine-231. Similar to the trend in Tau-5, 
mixed cytokines decreased the p-Tau [pS396] level 
to 0.60±0.07-fold (P<0.05 versus control group). 
Minocycline alone did not elicit any effect, ie 
1.22±0.11-fold, but could reverse the reduction in 
p-Tau [pS396] level when it was co-treated with 
mixed cytokines (1.13±0.13-fold, P<0.05 versus 
mixed cytokines group). There was no significant 
difference in the p-Tau (pT231) level amongst all 
groups.
Minocycline attenuated the decrease 
in drebrin protein expression and 
immunoreactivity induced by mixed cytokines
Mixed cytokines led to a significant decrease in 
the expression of drebrin (Fig 3) to 0.51±0.02-fold 
(P<0.01 versus control group). Minocycline per se 
did not change expression of drebrin, ie 1.12±0.12 
fold. However, co-treatment of mixed cytokines 
FIG 3.  Western blot analysis for Tau-5, p-Tau [pS396], p-Tau [pT231], and drebrin in the hippocampus of rats treated with mixed 
cytokines and/or 25mg minocycline. Representative blots for (a) Tau-5, (c) p-Tau [pS396], (e) p-Tau [pT231], and (g) drebrin, 
together with the corresponding densitometry measurements (b), (d), (f), and (h), respectively, are shown. Results are expressed 
as fold of control, and error bars represent SEM. Significant difference in MC versus control (P<0.05) and Mino+MC versus MC 
(P<0.05).
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with minocycline could partially suppress the 
reduction of drebrin protein triggered by mixed 
cytokines to 0.69±0.05-fold (P<0.05 versus mixed 
cytokines group). Such changes in drebrin protein 
expression were associated with a similar pattern 
of immunofluorescent staining at the CA3 region 
(Fig 5). Mixed cytokines reduced the abundance 
of drebrin puncta and its immunoreactivity. 
Minocycline alone did not seem to alter these two 
parameters. When co-treated with mixed cytokines, 
minocycline abolished the drop in the abundance of 
drebrin puncta and its immunoreactivity by mixed 
cytokines.
Discussion
In order to mimic cytokine storm, we injected 
intraperitoneally a mixture of cytokines comprised 
of IL-1β, IL-6, and TNF-α, IFN-α, IL-8, MCP-1, and 
MIP-1α. We chose to inject these cytokines because 
they have demonstrated an increase in blood and 
in nasal fluids during influenza infection. We also 
used nanogram levels of cytokines because in the 
presence of influenza infection, these cytokines 
exist at concentrations of pg/ml in blood.2 Based 
on the assumption that their in-vivo half-life ranges 
from minutes to hours, these cytokines would be 
able to last for hours in-vivo before they return 
to basal levels. We focused on any change that 
occurred within the hippocampus because damage 
in this region has been frequently reported in several 
models of seizure,4 ie the most common neurological 
complication in patients with influenza.
 Neuroinflammation is a common phenomenon 
that occurs in acute neurological complications, eg 
epilepsy, encephalitis, and encephalopathy, and in 
chronic neurodegenerative diseases, eg Alzheimer’s 
disease, Parkinson’s disease, and multiple sclerosis. 
Activation of astrocytes and microglia leads to 
production of inflammatory mediators such 
as cytokines, chemokines, and prostaglandins. 
These inflammatory mediators not only alter 
neurotransmitter, synaptic plasticity, neurotrophin 
signalling, and the cytoskeleton, but also influence 
mood, behaviour, and cognition.3 We showed that 
systemic injection of mixed cytokines induced 
signs of astrocytic and microglial activation within 
the dentate gyrus. Oral feeding of minocycline 
attenuated this activation. These results imply that 
cytokine storm may cause glial activation, and may 
be inhibited by minocycline.
 Tau protein associates with microtubules and 
stabilises them. In mature neurons, tau protein is 
predominately located along axons and is required 
for axonal growth and transport.5 The binding of tau 
protein to microtubules is in turn regulated by its 
phosphorylation. We asked whether mixed cytokines 
could alter the level of total tau protein and/or its 
phosphorylation at the residues serine 396 and 
threonine 231, and if yes, could minocycline hinder 
such changes? To our surprise, mixed cytokines 
decreased the amount of total tau, as revealed by 
decreases in Tau-5 immunoreactivity and protein 
(a)
(c)
(b)
(d)
FIG 4.  Fluorescent images of Tau-5 immunofluorescence staining, 1 day post-
treatment, in the CA3 region of rats treated with (a) control, (b) mixed cytokines, 
(c) 25 mg minocycline, and (d) 25 mg minocycline plus mixed cytokines. Arrows 
indicate increased number of cells having Tau-5 immunoreactivity in the cell body 
of the Mino group and MC+Mino group. Minocycline reverses the drop of Tau-5 
immunoreactivity by mixed cytokines.
FIG 5.  Fluorescent images of drebrin immunofluorescence staining, 1 day post-
treatment, in the CA3 region of rats treated with (a) control, (b) mixed cytokines, 
(c) 25 mg minocycline, and (d) 25 mg minocycline plus mixed cytokines. Minocycline 
hinders the decrease in drebrin puncta number and immunoreactivity by mixed 
cytokines.
(a)
(c)
(b)
(d)
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expression. Minocycline treatment restored Tau-5 
protein immunoreactivty and expression. Yet, it is 
notable that minocycline treatment, ie in both the 
minocycline group and co-treatment group, appeared 
to increase Tau-5 immunoreactivity in the cell bodies 
of parenchymal cells. Such disorganisation of tau 
protein into the cell body by minocycline was rather 
unexpected. Although the mis-sorting of tau protein 
into the cell body of neurons has been previously 
reported with beta-amyloid treatment, and it is 
thought to be undesirable,5 we are not sure whether 
this indicates a negative impact of minocycline in 
our model, and have not validated the cell type of 
these cells. In addition, mixed cytokines reduced 
the p-Tau [pS396] level and minocycline was able to 
attenuate it. Based on these results, we suggest that 
in our model mixed cytokines may have affected the 
dynamics of tau protein, and minocycline may have 
hindered these effects.
 Apart from tau protein, we also studied 
whether mixed cytokines altered drebrin, which is a 
binding protein of F-actin, the major cytoskeleton in 
dendritic spines.6 Drebrin regulates spine plasticity: 
overexpression of drebrin leads to elongation of 
dendritic spines in mature neurons,7 whereas 
down-regulation of drebrin expression by antisense 
oligonucleotides reduces the width and density of 
filapodia-spines in developing neurons.8 Our results 
showed that mixed cytokines decreased both drebrin 
immunoreactivity at the CA3 region and protein 
expression. Minocycline was able to attenuate 
such decrements induced by mixed cytokines. 
Such data raise the possibility that cytokine storm 
could modulate synaptic plasticity and spine 
morphogenesis, and minocycline may remove this 
modulation.
 Therefore, it could be seen that mixed 
cytokines induced activation of glia, and changes in 
the cytoskeleton-associated proteins tau and drebrin 
in the hippocampus 1 day post-treatment. An oral 
dose of minocycline at the time of mixed cytokine 
injection was able to inhibit glial activation and 
cytoskeleton-related changes. Although these results 
may suggest that minocycline can be effective in 
tackling glial activation and the neuronal cytoskeletal 
changes induced by cytokine storm, one should take 
into account several points before jumping to this 
conclusion. Firstly, minocycline was administered at 
the same time as mixed cytokines. In a clinical setting, 
a patient’s cytokine storm will have been present for 
1-2 days before the medical consultation. Hence, the 
toxicity of cytokine storm on the brain would have 
proceeded such that minocycline is no longer of any 
benefit. Secondly, rats were sacrificed 1 day post-
injection, but cytokine storm during influenza can 
last for up to 7 days. Hence, the experiment could be 
extended and include multiple injections of mixed 
cytokines and multiple oral doses of minocycline 
throughout the study period. This is particularly 
important because a longer cytokine storm could 
likely lead to more severe toxicity to the brain, and 
drug resistance to minocycline could develop after 
several doses and limit its effectiveness.
 Based on these results, we believe that 
minocycline is probably protective against the 
neuropathological impact of cytokine storm. Future 
studies should verify whether minocycline relieves 
the neurological complications caused by influenza 
infection.
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